ADCYAP1 and Parkinson disease: The neuroprotective properties of PACAP have also been demonstrated in a rat model of PD, where peptide administration prevented the degeneration of nigral dopaminergic neurons, slowed down cognitive decline, and ameliorated behavioral deficits by regulating dopamine levels and PD protein 7 (PARK7) [184].